if christmas comes around and this isn't below $10 i lost my gains and this market is fake.
LABU 70-80% gains since covered.
CRSP 90-100% gains since covered.
SGMO 30% gains since covered.
NGM 33% gains since covered.
ZIOP 20% gains since covered.
CLVS 533% gains since covered. ( I took home 280% )
With something like this you've gotta wait until at least AFTER the 3rd day. It's hard to post ideas on tradingview when the price is moving like that though lol
Entry level above daily resistance $10.65 =
Target price below monthly resistance $11.65.
Stock is running hard on momentum and maybe some fomo, much to risky to be opening a investment trade but still some upside potential for a trade.
Stock is running into a very strong area of resistance so caution is needed, it has risen very fast and can drop even faster....
Possible entry level on break above 100MA @ $7.00
Upside targets at resistance levels $7.75 & $8.90
Becoming overbought but very popular stock with day traders who watch for these gaps to fill.
Be ready to get out quick, could have hard drop.
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
CLVS
